Obese men have more advanced and more aggressive prostate cancer at time of surgery than non-obese men after adjusting for screening PSA level and age: Results from two independent nested case-control studies

Prostate Cancer and Prostatic Diseases

Volumn 16, Issue 4, 2013, Pages 352-356

  Parker, A S ^a   Thiel, D D ^a   Bergstralh, E ^b   Carlson, R E ^b   Rangel, L J ^b   Joseph, R W ^a   Diehl, N ^a   Karnes, R J ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Aggressiveness; Obesity; PSA; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CANCER LOCALIZATION; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; SEMINAL VESICLE DISEASE; UNITED STATES;

AGE FACTORS; AGED; AGED, 80 AND OVER; BODY MASS INDEX; CASE-CONTROL STUDIES; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; OBESITY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84887609075     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2013.27     Document Type: Article

References (22)

1. Hilton WM, Thompson Jr IM, Parekh DJ. Prostate cancer screening: navigating the controversy. In: Jones JSProstate Cancer Diagnosis. Humana Press, 2013, pp 11-26.
2. Barry M. Screening for prostate cancer-The Controversy that refuses to die. N Engl J Med 2009; 360: 1351-1354.
3. Grubb III RL, Black A, Izmirlian G, Hickey TP, Pinsky PF, Mabie JE et al. Serum prostate-specific antigen hemodilution among obese men undergoing screening in the prostate, lung, colorectal, and ovarian cancer Screening Trial. Cancer Epidemiol Biomarkers Prev 2009; 18: 748-751.
4. Banez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C et al. Obesityrelated plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 2007; 298: 2275-2280.
5. Dreicer R. Why do obese men have lower PSA concentrations? Journal Watch. N Engl J Med 2007; 20: 3-7.
6. Culp S, Porter M. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men. BJU Int 2009; 104: 1457-1461.
7. Ohwaki K, Endo F, Muraishi O, Hiramatsu S, Yano E. Relationship between prostate-specific antigen and hematocrit: does hemodilution lead to lower PSA concentrations in men with a higher body mass index? Urology 2010; 75: 648-652.
8. Rundle A, Neugut AI. Obesity and screening PSA levels among men undergoing an annual physical exam. Prostate 2008; 68: 373-380.
9. Mitchell CR, Umbreit EC, Rangel LJ, Bergstralh EJ, Karnes RJ. Does body mass index ''dilute'' the predictive property of prostate-specific antigen for tumor volume at radical prostatectomy? Urology 2011; 78: 868-872.
10. Pater LE, Hart KW, Blonigen BJ, Lindsell CJ, Barrett WL. Relationship between prostate-specific antigen, age, and body mass index in a prostate cancer screening population. Am J Clin Oncol 2012; 35: 490-492.
11. Rundle A, Richards C, Neugut AI. Body composition, abdominal fat distribution, and prostate-specific antigen test results. Cancer Epidemiol Biomarkers Prev 2009; 18: 331-336.
12. Parekh N, Lin Y, Dipaola RS, Marcella S, Lu-Yao G. Obesity and prostate cancer detection: insights from three national surveys. Am J Med 2010; 123: 829-835.
13. Liang Y, Ankerst DP, Sanchez M, Leach RJ, Thompson IM. Body mass index adjusted prostate-specific antigen and its application for prostate cancer screening. Urology 2010; 76: e1-e6.
14. Rundle A, Richards C, Neugut AI. Hemodilution of prostate-specific antigen levels among obese men. Cancer Epidemiol Biomarkers Prev 2009; 18: 2343.
15. Skolarus TA, Wolin KY, Grubb RL. III. The effect of body mass index on PSA levels and the development, screening and treatment of prostate cancer. Nat Clin Pract Urol 2007; 4: 605-614.
16. Putnam SD, Cerhan JR, Parker AS, Bianchi GD, Wallace RB, Cantor KP et al. Lifestyle and anthropometric risk factors for prostate cancer in a cohort of Iowa men. Ann Epidemiol 2000; 10: 361-369.
17. Wright ME, Chang SC, Schatzkin A, Albanes D, Kipnis V, Mouw T et al. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 2007; 109: 675-684.
18. Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW et al. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2006; 15: 1977-1983.
19. Rodriguez C, Freeland SJ, Deka A, Jacobs EJ, McCullough ML, Patel AV et al. Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 2007; 16: 63-69.
20. Banez LL, Albisinni S, Freedland SJ, Tubaro A, De Nunzio . The impact of obesity on the predictive accuracy of PSA in men undergoing prostate biopsy. World J Urol 2012, [Epub ahead of print].
21. Parekh N, Lin Y, DiPaola RS, Marcella S, Lu-Yao G. Obesity and prostate cancer detection: insights from three national surveys. Am J Med 2010; 123: 829-835.
22. Freedland SJ, Platz EA. Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev 2007; 29: 88-97.